Current understanding proposes that CAFs in HER2+ breast cancer confer resistance to Herceptin by orchestrating the loss of PTEN or activating the IL-6/STAT-3/NF-κB signaling pathway [51]. Here, ERBB2 is linked to breast carcinoma.